Sherbrooke Park Advisers LLC Apellis Pharmaceuticals, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $230 Billion
- Q2 2025
A detailed history of Sherbrooke Park Advisers LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 15,939 shares of APLS stock, worth $330,415. This represents 0.12% of its overall portfolio holdings.
Number of Shares
15,939Holding current value
$330,415% of portfolio
0.12%Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
134MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$253 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$247 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$211 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$202 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$186 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.28B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...